Free delivery on orders over £50

SHARE

[reviews_rating summary="no" avatar="false" icon="no" min=4 excerpt=160 more="read more" attribution="no" limit=10 view=1 excerpt=180 loop="true" interval=10]

Vulvodynia is a chronic vulvar pain condition that can affect sitting, exercise, intimacy and everyday comfort. Many people work through several treatments, from topical anaesthetics to neuropathic pain medicines and pelvic floor physiotherapy, and still find their symptoms are not fully controlled. For this group, low-dose naltrexone (LDN) is emerging as a promising add-on option worth discussing with a prescriber.

LDN is an inexpensive, long-established medicine used at a fraction of its usual dose. It has a favourable safety profile, and early clinical reports in vulvodynia have been encouraging. This article explains what has been reported so far, why LDN makes sense for this type of pain, and what to consider before trying it.

Key takeaways

  • A 2024 case series reported symptom improvement in all three patients with hard-to-treat vulvodynia who added LDN, with no reported side effects. [1]
  • LDN is generally well tolerated, which makes it an attractive option to consider when other treatments have not worked. [2]
  • Its proposed effects on pain signalling and nervous system inflammation fit well with how chronic vulvar pain is understood. [3]
  • The evidence is still early and based on patient-reported outcomes, so larger trials are needed to confirm how well it works. [1], [2]
  • LDN can interfere with opioid pain medicines, so prescriber advice is essential. [3]

Encouraging results in hard-to-treat vulvodynia

The most direct evidence comes from a case series published in 2024. It described three patients with chronic vulvodynia whose symptoms had remained poorly controlled despite standard treatment. Each started LDN as an additional pain therapy. All three reported that their symptoms improved, and none reported side effects. [1]

These were patients for whom usual approaches had not been enough, so a consistent improvement across all three is a meaningful early signal. The findings are based on patients’ own reports of their symptoms, which is appropriate for a condition where pain and quality of life are the outcomes that matter most, although it also means the results need confirming in controlled studies.

Why LDN makes sense for vulvar pain

Vulvodynia is increasingly understood as a neuropathic and centralised pain condition, in which the nervous system becomes sensitised and continues to amplify pain signals. LDN is thought to act on exactly these processes. At low doses, a brief opioid receptor blockade may boost the body’s own pain-relieving opioid signalling, and LDN may also calm inflammatory activity in immune and glial cells within the nervous system. [3]

This biological rationale is one reason LDN has been explored across other chronic pain conditions with similar features, including fibromyalgia, complex regional pain syndrome and other neuropathic pain. [2], [3] While results in other conditions cannot prove that LDN works in vulvodynia, they help explain why clinicians see it as a logical option to try.

A favourable safety profile

One of LDN’s main strengths is its tolerability. Across the wider literature, LDN is generally well tolerated at low doses. [2] For people with refractory vulvodynia, where some alternative treatments carry troublesome side effects, this makes LDN a reasonable option to discuss when the potential benefit is weighed against a relatively low risk.

LDN is an opioid antagonist, however. Anyone taking opioid pain medicines, or likely to need opioid pain relief, for example before planned surgery, should discuss LDN with a prescriber first, as it can interfere with opioid treatment. [3]

Where LDN fits in treatment

LDN is not a replacement for established vulvodynia care, and it is best considered as an add-on when standard treatments have not given enough relief. A 2026 narrative review noted that much of the LDN literature consists of small studies with subjective outcomes, and that the evidence does not yet support routine use. It suggested that, where LDN is considered in treatment-resistant cases, its experimental status should be clearly explained. [2] Refractory vulvodynia is precisely the situation in which that informed, shared decision can be appropriate.

Because naltrexone is an established, off-patent medicine, there is little commercial incentive to fund large trials, which is one reason the evidence has lagged behind clinical interest. Larger controlled studies would help confirm how much LDN helps, which vulvodynia subtypes respond best and what dose works best.

Is low-dose naltrexone right for me?

In the UK, LDN is a prescription-only medicine used off-label for vulvodynia. If your symptoms remain difficult to control despite standard treatment, it may be worth discussing with a prescriber who can review your medical history, current medicines and treatment goals, and talk through the potential benefits and the current limits of the evidence with you.

References

[1] R. T. Sullender, R. Silverstein, D. M. Goodwin, A. McClurg, and E. T. Carey, “Low-dose naltrexone as a treatment for vulvodynia: A case series,” Case Reports in Women’s Health, 2024, doi: 10.1016/j.crwh.2024.e00677.

[2] A. H. K. Gouda, N. E. C. Aitcheson, and K. J. Steadman, “Low-dose naltrexone: What is the evidence? A narrative review,” Advances in Therapy, 2026, doi: 10.1007/s12325-026-03612-5.

[3] A. McKenzie et al., “Low-dose naltrexone in chronic pain management: Mechanisms, evidence, and clinical implications,” Journal of Personalized Medicine, 2026, doi: 10.3390/jpm16030151.

Error getting reviews. Possible timeout.

{"47351":47351,"42749":42749,"42605":42605,"42603":42603,"42600":42600,"42593":42593,"42583":42583,"42567":42567,"42547":42547,"40672":40672,"40495":40495,"40227":40227,"40156":40156,"37533":37533,"37525":37525,"37518":37518,"37510":37510,"37499":37499,"37025":37025,"36969":36969,"36383":36383,"35982":35982,"35862":35862,"35865":35865,"35688":35688,"35611":35611,"35477":35477,"35417":35417,"35106":35106}